Journal of Traditional Chinese Medicine ›› 2023, Vol. 43 ›› Issue (2): 221-230.DOI: 10.19852/j.cnki.jtcm.20221108.005
• Meta Analysis • Previous Articles Next Articles
ZHANG Junli(), HE Ying, ZHANG Xia, FU Hongfang, HU Xiaoyu()
Received:
2022-01-22
Accepted:
2022-08-18
Online:
2023-04-15
Published:
2023-03-14
Contact:
Prof. HU Xiaoyu, Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. xiaoyuhu202010@163.com; Dr. Zhang Junli, Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, China. ZhangJunLi@stu.cdutcm.edu.cn. Telephone: +86-15281063757
Supported by:
ZHANG Junli, HE Ying, ZHANG Xia, FU Hongfang, HU Xiaoyu. Fuzheng Huayu preparation (扶正化瘀胶囊/片) combined with tenofovir disoproxil fumarate on hepatitis B: a systematic review and Meta-analysis[J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 221-230.
Figure 1 Flow diagram of the search and selection process CNKI: China National Knowledge Infrastructure Database; VIP: China Science and Technology Journal Database.
Study | Sample Size (male) | Age Mean±SD (years) | Disease progression | Intervention | Duration | Outcome | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
E | C | E | C | E | C | ||||||
Hu HF et al 2021 | 75 (46) | 75 (44) | (45.26±5.23) | (45.69±6.86) | hepatitis B cirrhosis | FZHY capsule +TDF | TDF | 24w | ①②③④⑤⑥⑦⑧ | ||
Li W 2021 | 58 (29) | 58 (28) | (48.66±6.12) | (47.92±5.87) | hepatitis B cirrhosis | FZHY capsule +TDF | TDF | 24w | ①② | ||
Ye XT et al 2021 | 50 (?) | 50 (?) | (42.50±8.46) | (42.50±8.46) | hepatitis B cirrhosis | FZHY capsule +TDF | TDF | 18m | ⑤⑥⑦ | ||
Zhang ZG et al 2019 | 60 (41) | 60 (39) | (51.27±6.89) | (50.13±7.28) | hepatitis B cirrhosis | FZHY capsule +TDF | TDF | 48w | ⑤⑥⑦⑧ | ||
Yu J et al 2018 | 40 (30) | 40 (28) | (47.6±9.5) | (47.7±9.2) | hepatitis B cirrhosis | FZHY capsule +TDF | TDF | 48w | ①②④⑤⑥⑦⑧ | ||
Li TH et al 2020 | 120 (74) | 120 (71) | (37.59±8.10) | (37.42±8.25) | chronic hepatitis B | FZHY tablet +TDF | TDF | 3m | ①②③④ | ||
Wang N 2020 | 48 (25) | 48 (27) | (43.6±1.4) | (43.2±1.7) | chronic hepatitis B | FZHY capsule +TDF | TDF | 8w | ①②③④⑤⑥⑦⑧ | ||
Wang XH 2019 | 44 (26) | 44 (28) | (39.56±4.58) | (39.13±4.47) | chronic hepatitis B | FZHY capsule +TDF | TDF | 12m | ①②③④⑤⑥⑦⑧ |
Table 1 Characteristics of the included studies
Study | Sample Size (male) | Age Mean±SD (years) | Disease progression | Intervention | Duration | Outcome | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
E | C | E | C | E | C | ||||||
Hu HF et al 2021 | 75 (46) | 75 (44) | (45.26±5.23) | (45.69±6.86) | hepatitis B cirrhosis | FZHY capsule +TDF | TDF | 24w | ①②③④⑤⑥⑦⑧ | ||
Li W 2021 | 58 (29) | 58 (28) | (48.66±6.12) | (47.92±5.87) | hepatitis B cirrhosis | FZHY capsule +TDF | TDF | 24w | ①② | ||
Ye XT et al 2021 | 50 (?) | 50 (?) | (42.50±8.46) | (42.50±8.46) | hepatitis B cirrhosis | FZHY capsule +TDF | TDF | 18m | ⑤⑥⑦ | ||
Zhang ZG et al 2019 | 60 (41) | 60 (39) | (51.27±6.89) | (50.13±7.28) | hepatitis B cirrhosis | FZHY capsule +TDF | TDF | 48w | ⑤⑥⑦⑧ | ||
Yu J et al 2018 | 40 (30) | 40 (28) | (47.6±9.5) | (47.7±9.2) | hepatitis B cirrhosis | FZHY capsule +TDF | TDF | 48w | ①②④⑤⑥⑦⑧ | ||
Li TH et al 2020 | 120 (74) | 120 (71) | (37.59±8.10) | (37.42±8.25) | chronic hepatitis B | FZHY tablet +TDF | TDF | 3m | ①②③④ | ||
Wang N 2020 | 48 (25) | 48 (27) | (43.6±1.4) | (43.2±1.7) | chronic hepatitis B | FZHY capsule +TDF | TDF | 8w | ①②③④⑤⑥⑦⑧ | ||
Wang XH 2019 | 44 (26) | 44 (28) | (39.56±4.58) | (39.13±4.47) | chronic hepatitis B | FZHY capsule +TDF | TDF | 12m | ①②③④⑤⑥⑦⑧ |
Figure 2 Risk of bias summary and graph A: risk of bias summary: judgements about each risk of bias item for each included study. “?”: unclear risk of bias; “+”: low risk of bias; “-”: high risk of bias; B: risk of bias graph: judgements about each risk of bias item presented as percentages across all included studies.
Figure 3 Forest plot of outcomes of the indicators (part one) A: forest plot of alanine transaminase levels; B: forest plot of aspartate aminotransferase levels; C: forest plot of albumin levels; D: forest plot of total bilirubin levels.
Figure 4 Forest plot of outcomes of the indicators (part two) A: forest plot of hyaluronic acid levels; B: forest plot of type III procollagen levels; C: forest plot of laminin levels; D: forest plot of type IV collagen levels.
Indicator | Duration (weeks) | Number of studies | Heterogeneity | Model | Statistical analyses | |||
---|---|---|---|---|---|---|---|---|
P value | I2 score (%) | MD/SMD | 95% CI | P value | ||||
ALT | ≤ 24 | 4 | < 0.001 | 98 | Random | -13.85 | -22.16 to -5.54 | 0.001 |
> 24 | 2 | 0.25 | 25 | Fixed | -17.54 | -23.39 to -11.70 | < 0.001 | |
AST | ≤ 24 | 4 | < 0.001 | 97 | Random | -9.04 | -14.29 to -3.79 | < 0.001 |
> 24 | 2 | 0.002 | 90 | Random | -29.71 | -48.79 to -10.63 | 0.002 | |
ALB | ≤ 24 | 3 | < 0.001 | 95 | Random | 1.86 | -1.38 to 5.11 | 0.26 |
> 24 | 1 | - | - | - | 4.81 | 2.97 to 6.65 | < 0.001 | |
TBiL | ≤ 24 | 3 | < 0.001 | 88 | Random | -4.04 | -6.38 to -1.71 | < 0.001 |
> 24 | 2 | 0.08 | 68 | Random | -11.64 | -19.52 to -3.76 | 0.004 | |
HA | ≤ 24 | 2 | < 0.001 | 96 | Random | -3.20 | -5.38 to -1.02 | 0.004 |
>24 | 4 | < 0.001 | 95 | Random | -1.66 | -2.69 to -0.63 | 0.002 | |
PCIII | ≤ 24 | 2 | < 0.001 | 97 | Random | -1.36 | -3.18 to -0.47 | 0.15 |
> 24 | 4 | < 0.001 | 89 | Random | -1.34 | -2.01 to -0.66 | < 0.001 | |
LN | ≤ 24 | 2 | 0.01 | 84 | Random | -4.02 | -5.18 to -2.86 | < 0.001 |
> 24 | 4 | 0.005 | 76 | Random | -0.86 | -1.30 to -0.43 | < 0.001 | |
IV-C | ≤ 24 | 2 | 0.83 | 0 | Fixed | -3.60 | -4.00 to -3.19 | < 0.001 |
> 24 | 3 | 0.02 | 74 | Random | -1.74 | -2.29 to -1.20 | < 0.001 |
Table 2 Results of subgroup analysis based on treatment duration
Indicator | Duration (weeks) | Number of studies | Heterogeneity | Model | Statistical analyses | |||
---|---|---|---|---|---|---|---|---|
P value | I2 score (%) | MD/SMD | 95% CI | P value | ||||
ALT | ≤ 24 | 4 | < 0.001 | 98 | Random | -13.85 | -22.16 to -5.54 | 0.001 |
> 24 | 2 | 0.25 | 25 | Fixed | -17.54 | -23.39 to -11.70 | < 0.001 | |
AST | ≤ 24 | 4 | < 0.001 | 97 | Random | -9.04 | -14.29 to -3.79 | < 0.001 |
> 24 | 2 | 0.002 | 90 | Random | -29.71 | -48.79 to -10.63 | 0.002 | |
ALB | ≤ 24 | 3 | < 0.001 | 95 | Random | 1.86 | -1.38 to 5.11 | 0.26 |
> 24 | 1 | - | - | - | 4.81 | 2.97 to 6.65 | < 0.001 | |
TBiL | ≤ 24 | 3 | < 0.001 | 88 | Random | -4.04 | -6.38 to -1.71 | < 0.001 |
> 24 | 2 | 0.08 | 68 | Random | -11.64 | -19.52 to -3.76 | 0.004 | |
HA | ≤ 24 | 2 | < 0.001 | 96 | Random | -3.20 | -5.38 to -1.02 | 0.004 |
>24 | 4 | < 0.001 | 95 | Random | -1.66 | -2.69 to -0.63 | 0.002 | |
PCIII | ≤ 24 | 2 | < 0.001 | 97 | Random | -1.36 | -3.18 to -0.47 | 0.15 |
> 24 | 4 | < 0.001 | 89 | Random | -1.34 | -2.01 to -0.66 | < 0.001 | |
LN | ≤ 24 | 2 | 0.01 | 84 | Random | -4.02 | -5.18 to -2.86 | < 0.001 |
> 24 | 4 | 0.005 | 76 | Random | -0.86 | -1.30 to -0.43 | < 0.001 | |
IV-C | ≤ 24 | 2 | 0.83 | 0 | Fixed | -3.60 | -4.00 to -3.19 | < 0.001 |
> 24 | 3 | 0.02 | 74 | Random | -1.74 | -2.29 to -1.20 | < 0.001 |
1. |
Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018; 3: 383-403.
DOI URL |
2. |
Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. World J Gastrointest Pharmacol Ther 2021; 12: 56-78.
DOI PMID |
3. |
European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370-98.
DOI PMID |
4. |
Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
DOI PMID |
5. |
Koyama Y, Xu J, Liu X, Brenner DA. New developments on the treatment of liver fibrosis. Dig Dis 2016; 34: 589-96.
DOI PMID |
6. |
Tan Z, Sun H, Xue T, et al. Liver fibrosis: therapeutic targets and advances in drug therapy. Front Cell Dev Biol 2021; 9: 730176.
DOI URL |
7. |
Zhao CQ, Zhou Y, Ping J, Xu LM. Traditional Chinese Medicine for treatment of liver diseases: progress, challenges and opportunities. J Integr Med 2014; 12: 401-8.
DOI URL |
8. |
Liu W, Li Z, Sun Z, et al. The components data of Fuzheng Huayu extracts, cordyceps sinensis mycelia polysaccharide, gypenosides and amygdalin. Data Brief 2019; 25: 104087.
DOI URL |
9. |
Li H. Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula. J Ethnopharmacol 2020; 251: 112442.
DOI URL |
10. |
Feng Y, Cheung KF, Wang N, Liu P, Nagamatsu T, Tong Y. Chinese medicines as a resource for liver fibrosis treatment. Chin Med 2009; 4: 16.
DOI |
11. | Tang LR, Guo T, Tao YY, Mu YP, Liu CH. A systematic review of combinative effects of Fuzheng Huayu capsule with nucleotide analogues on liver fibrosis due to chronic hepatitis B. Zhong Xi Yi Jie He Gan Bing Za Zhi 2013; 23: 183-7. |
12. |
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med 2021; 18: e1003583.
DOI URL |
13. |
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
DOI URL |
14. | Wang N. Effects of tenofovir dipivoxil fumarate tablets combined with Fuzheng Huayu capsule on liver function in patients with hepatitis B. Zhong Guo Yao Wu Jing Ji Xue 2020; 15: 111-4. |
15. | Li TH, Fu YC, Yang YK, Cui YF, Li QY, Tian Y. Clinical study on Fuzheng Huayu tablets combined with tenofovir dipivoxil in treatment of chronic hepatitis B. Xian Dai Yao Wu Yu Lin Chuang 2020; 35: 1787-90. |
16. | Wang XH. Clinical efficacy of tenofovir disoproxil fumarate combined with Fuzheng Huayu capsule in the treatment of chronic hepatic fibrosis of type B hepatitis. Yi Xue Shi Liao Yu Jian Kang 2019; 17: 166-7. |
17. | Hu HF, Liu W, Tan L. Effects of tenofovir disoproxil fumarate combined with Fuzheng Huayu on liver fibrosis degree and immune status of patients with hepatitis B cirrhosis. He Bei Yi Xue 2021; 27: 686-92. |
18. | Yu J, Wang XB, Cui WL. Clinical observation of tenofovir disoproxil fumarate combined with Fuzheng Huayu capsule in the treatment of hepatitis B cirrhosis. Lin Chuang Yan Jiu 2018; 26: 85-7. |
19. | Li W. Effect of tenofovir dipivoxil and Fuzheng Huayu capsule in the treatment of hepatitis B cirrhosis. Zhong Wai Yi Xue Yan Jiu 2021; 19: 16-8. |
20. | Ye XT, Sun QF, Fu RQ, Hong L, Zhou Y, Zhang WW. Clinical efficacy of tenofovir and Fuzheng Huayu capsule in treatment of patients with chronic hepatitis B liver cirrhosis. Shi Yong Gan Zang Bing Za Zhi 2021; 24: 143-4. |
21. | Zhang ZG, Gao FZ, Gao HB. Effect of Fuzheng Huayu capsule combined with tenofovir disoproxil fumarate on APRI score and serum indexes of hepatic fibrosis in compensated hepatitis B cirrhosis. Zhong Guo Shi Yong Yi Yao 2019; 14: 89-91. |
22. |
Agarwal K, Brunetto M, Seto WK, et al. 96 weeks treatment of tenofovir alafenamide vs tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 2018; 68: 672-81.
DOI PMID |
23. |
Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol 2015; 7: 1541-52.
DOI PMID |
24. |
Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75.
DOI PMID |
25. |
Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014; 59: 434-42.
PMID |
26. | Yang L, Liao JB, Liu AQ, et al. Advances in Traditional Chinese Medicine for liver disease therapy in 2020. Tradit Med Res 2021; 6: 133-46. |
27. | Cao M, Miao J, Wang L, Liu HZ, Cui HT, Bian YH. The advances of Traditional Chinese Medicine in the treatment of liver diseases in 2019. Tradit Med Res 2020; 5: 261-71. |
28. |
Liu P, Hu YY, Liu C, et al. Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B. World J Gastroenterol 2005; 11: 2892-9.
DOI URL |
29. |
Deng X, Liang J, Wu FS, Li YB, Zhang YP, Tang YF. Influence of Fuzheng Huayu tablet on mental state and social function of patients with post-hepatitis B liver cirrhosis. Chin J Integr Med 2012; 18: 466-72.
DOI PMID |
30. |
Wang QL, Tao YY, Shen L, Cui HY, Liu CH. Chinese herbal medicine Fuzheng Huayu recipe inhibits liver fibrosis by mediating the transforming growth factor-β1/smads signaling pathway. Zhong Xi Yi Jie He Xue Bao 2012; 10: 561-8.
DOI URL |
31. |
Chen J, Hu Y, Chen L, Liu W, Mu Y, Liu P. The effect and mechanisms of Fuzheng Huayu formula against chronic liver diseases. Biomed Pharmacother 2019; 114: 108846.
DOI URL |
32. |
Ayling RM. Pitfalls in the interpretation of common biochemical tests. Postgrad Med J 2000; 76: 129-32.
PMID |
33. |
Agbim U, Asrani SK. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. Expert Rev Gastroenterol Hepatol 2019; 13: 361-74.
DOI URL |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
Sponsored by China Association of Chinese Medicine
& China Academy of Chinese Medical Sciences
16 Nanxiaojie, Dongzhimen Nei, Beijing, China. 100700 Email: jtcmen@126.com
Copyright 2020 Journal of Traditional Chinese Medicine. All rights reserved.